Breaking News

 Outlook dims for ProQR’s vision loss therapy

Not rendering correctly? View this email as a web page here.

The future of regulatory labeling compliance depends on technology adoption

By Cham Williams Friday, February 11, 2022 6:16 PM

The life sciences industry is more quickly adapting to new methods, standards and requirements. The focus is now on how to drive greater data governance and quality through a unified framework.  The challenge comes in instituting a framework that will meet regulatory and labeling requirements.

Read more »

Outlook dims for ProQR's RNA therapy for vision loss following failure in key test

By Frank Vinluan Friday, February 11, 2022 3:34 PM

The lead RNA therapy from ProQR Therapeutics has failed the main and secondary goals of a pivotal study testing it as a treatment for a rare, inherited vision disorder. Despite the disappointing preliminary data, the biotech said it remains confident in the technology that produced the experimental therapy, sepofarsen, and the Phase 2/3 study will continue.

Read more »

Now is the time to tackle medication adherence in clinical trials

By Bernard Vrijens Friday, February 11, 2022 2:54 PM

Integrating advanced technologies, including smart packaging and powerful data analytics, is driving a revolution in adherence monitoring that is accelerating drug development timelines, lowering clinical research costs and making trials safer for participants.

Read more »

   

No comments